Dimethyl fumarate - new measures to minimise leukoencephalopathy risk

Revised monitoring recommendations have been issued to reduce the risk of progressive multifocal leukoencephalopathy (PML) in patients with MS receiving dimethyl fumarate (Tecfidera).

by Chloe Harman

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package